Identification and Characterization of a Misfolded Monomeric Serpin Formed at Physiological Temperature

Journal of Molecular Biology

Volumn 403, Issue 3, 2010, Pages 459-467

  Pearce, M C ^a   Powers, G A ^a   Feil, S C ^b,c   Hansen, G ^b,d   Parker, M W ^b,c   Bottomley, S P ^a  

^a MONASH UNIVERSITY   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Antichymotrypsin; Conformational change; Polymerization; Protein misfolding; Serpin

Indexed keywords

CHYMOTRYPSIN INHIBITOR; MONOMER; POLYMER; PROTEINASE; SERINE PROTEINASE INHIBITOR; ANTICHYMOTRYPSIN II;

ARTICLE; CONFORMATIONAL TRANSITION; ENERGY; ENVIRONMENTAL STRESS; ENZYME INHIBITION; PH; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; TECHNIQUE; TEMPERATURE; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; KINETICS; METABOLISM; PROTEIN CONFORMATION; THERMODYNAMICS;

CRYSTALLOGRAPHY, X-RAY; HUMANS; KINETICS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN FOLDING; SERPINS; THERMODYNAMICS;

EID: 77957756475     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.09.007     Document Type: Article

References (35)

1. Cabrita L.D., Bottomley S.P. How do proteins avoid becoming too stable? Biophysical studies into metastable proteins. Eur. Biophys. J. 2004, 33:83-88.
2. Im H., Woo M.S., Hwang K.Y., Yu M.H. Interactions causing the kinetic trap in serpin protein folding. J. Biol. Chem. 2002, 277:46347-46354.
3. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 1984, 177:531-557.
4. George R.B., Richardson J.V. Alpha-1-antitrypsin deficiency and emphysema. J. La. State Med. Soc. 1973, 125:315-319.
5. Lomas D.A. Molecular mousetraps, alpha1-antitrypsin deficiency and the serpinopathies. Clin. Med. 2005, 5:249-257.
6. Lomas D.A., Evans D.L., Finch J.T., Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992, 357:605-607.
7. Davis R.L., Shrimpton A.E., Holohan P.D., Bradshaw C., Feiglin D., Collins G.H., et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999, 401:376-379.
8. Zhou A., Huntington J.A., Carrell R.W. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999, 94:3388-3396.
9. Huntington J.A., Read R.J., Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000, 407:923-926.
10. Stratikos E., Gettins P.G. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into beta-sheet A. Proc. Natl Acad. Sci. USA 1999, 96:4808-4813.
11. Tew D.J., Bottomley S.P. Intrinsic fluorescence changes and rapid kinetics of proteinase deformation during serpin inhibition. FEBS Lett. 2001, 494:30-33.
12. Gooptu B., Hazes B., Chang W.S., Dafforn T.R., Carrell R.W., Read R.J., Lomas D.A. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc. Natl Acad. Sci. USA 2000, 97:67-72.
13. Munch M., Heegaard C., Jensen P.H., Andreasen P.A. Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett. 1991, 295:102-106.
14. Beinrohr L., Harmat V., Dobo J., Lorincz Z., Gal P., Zavodszky P. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J. Biol. Chem. 2007, 282:21100-21109.
15. Mottonen J., Strand A., Symersky J., Sweet R.M., Danley D.E., Geoghegan K.F., et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992, 355:270-273.
16. Lomas D.A., Elliott P.R., Chang W.S., Wardell M.R., Carrell R.W. Preparation and characterization of latent alpha 1-antitrypsin. J. Biol. Chem. 1995, 270:5282-5288.
17. Sivasothy P., Dafforn T.R., Gettins P.G., Lomas D.A. Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. J. Biol. Chem. 2000, 275:33663-33668.
18. Yamasaki M., Li W., Johnson D.J., Huntington J.A. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 2008, 455:1255-1258.
19. Faber J.P., Poller W., Olek K., Baumann U., Carlson J., Lindmark B., Eriksson S. The molecular basis of alpha 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J. Hepatol. 1993, 18:313-321.
20. Chang W.S., Lomas D.A. Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema. J. Biol. Chem. 1998, 273:3695-3701.
21. Bruce D., Perry D.J., Borg J.Y., Carrell R.W., Wardell M.R. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn→Asp). J. Clin. Invest. 1994, 94:2265-2274.
22. Dafforn T.R., Pike R.N., Bottomley S.P. Physical characterization of serpin conformations. Methods 2004, 32:150-158.
23. Wardell M.R., Chang W.S., Bruce D., Skinner R., Lesk A.M., Carrell R.W. Preparative induction and characterization of l-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry 1997, 36:13133-13142.
24. Mast A.E., Enghild J.J., Pizzo S.V., Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991, 30:1723-1730.
25. Devlin G.L., Carver J.A., Bottomley S.P. The selective inhibition of serpin aggregation by the molecular chaperone, alpha-crystallin, indicates a nucleation-dependent specificity. J. Biol. Chem. 2003, 278:48644-48650.
26. Chow M.K., Lomas D.A., Bottomley S.P. Promiscuous beta-strand interactions and the conformational diseases. Curr. Med. Chem. 2004, 11:491-499.
27. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
28. Cabrita L.D., Dai W., Bottomley S.P. A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production. BMC Biotechnol. 2006, 6:12.
29. Pearce M.C., Cabrita L.D., Rubin H., Gore M.G., Bottomley S.P. Identification of residual structure within denatured antichymotrypsin: implications for serpin folding and misfolding. Biochem. Biophys. Res. Commun. 2004, 324:729-735.
30. Devlin G.L., Parfrey H., Tew D.J., Lomas D.A., Bottomley S.P. Prevention of polymerization of M and Z alpha1-antitrypsin (alpha1-AT) with trimethylamine N-oxide. Implications for the treatment of alpha1-AT deficiency. Am. J. Respir. Cell Mol. Biol. 2001, 24:727-732.
31. Leslie A.G.W. Jt. CCP4+ESF-EAMCB Newsl. Protein Crystallogr. 1992, No. 26.
32. Collaborative Computational Project Number The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. Sect. D 1994, 50:760-763.
33. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. Sect. A 1994, 50:157-163.
34. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 2004, 60:2126-2132.
35. Murshudov G., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D 1997, 53:240-255.